Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953. doi: 10.1002/ijc.31937
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154(2):360–373. doi: 10.1053/j.gastro.2017.08.023
   PubMed Web of Science ®Google Scholar
• Zhang HZ, Jin GF, Shen HB. Epidemiologic differences in esophageal cancer between Asian and Western populations. Chin J Cancer. 2012;31(6):281–286. doi: 10.5732/cjc.011.10390
   PubMed Web of Science ®Google Scholar
• Yang Z, Zeng H, Xia R, et al. Annual cost of illness of stomach and esophageal cancer patients in urban and rural areas in China: a multi-center study. Chin J Cancer Res. 2018;30(4):439–448. doi: 10.21147/j.issn.1000-9604.2018.04.07
   PubMed Web of Science ®Google Scholar
• Pennathur A, Gibson MK, Jobe BA, et al. Oesophageal carcinoma. Lancet. 2013;381(9864):400–412. doi: 10.1016/S0140-6736(12)60643-6
   PubMed Web of Science ®Google Scholar
• Rustgi AK, El-Serag HB, Ingelfinger JR. Esophageal carcinoma. N Engl J Med. 2014;371(26):2499–2509. doi: 10.1056/NEJMra1314530
   PubMed Web of Science ®Google Scholar
• Muro K, Lordick F, Tsushima T, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30(1):34–43. doi: 10.1093/annonc/mdy498
   PubMed Web of Science ®Google Scholar
• Ajani JA, D’Amico TA, Bentrem DJ, et al. Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(7):855–883. doi: 10.6004/jnccn.2019.0033
   PubMed Web of Science ®Google Scholar
• Liu S, Jiang N, Dou L, et al. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China. Front Immunol. 2023;14:1172242–1172251. doi: 10.3389/fimmu.2023.1172242
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi: 10.1126/science.aar4060
   PubMed Web of Science ®Google Scholar
• Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015;6(6):3479–3492. doi: 10.18632/oncotarget.2980
   PubMedGoogle Scholar
• Wang ZX, Cui C, Yao J, et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial. Cancer Cell. 2022;40(3):277–88.e3. doi: 10.1016/j.ccell.2022.02.007
   PubMed Web of Science ®Google Scholar
• Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010;9(3):203–214. doi: 10.1038/nrd3078
   PubMed Web of Science ®Google Scholar
• Saltz LB. Perspectives on cost and value in cancer care. JAMA Oncol. 2016;2(1):19–21. doi: 10.1001/jamaoncol.2015.4191
   PubMed Web of Science ®Google Scholar
• Liu G, Hu S, Wu J, et al. China guidelines for pharmacoeconomic evaluations. Beijing: China Market Press; 2020.
   Google Scholar
• Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518–528. doi: 10.1111/j.1524-4733.2004.75003.x
   PubMed Web of Science ®Google Scholar
• Thokala P, Ochalek J, Leech AA, et al. Cost-effectiveness thresholds: the past, the present and the future. Pharmacoeconomics. 2018;36(5):509–522. doi: 10.1007/s40273-017-0606-1
   PubMed Web of Science ®Google Scholar
• Tzanetakos C, Gourzoulidis G. Does a standard cost-effectiveness threshold exist? The case of Greece. Value Health Reg Issues. 2023;36:18–26. doi: 10.1016/j.vhri.2023.02.006
   PubMedGoogle Scholar
• Latimer NR. Survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013;33(6):743–754. doi: 10.1177/0272989X12472398
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9–21. doi: 10.1186/1471-2288-12-9
   PubMed Web of Science ®Google Scholar
• Andersson TM, Dickman PW, Eloranta S, et al. Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models. BMC Med Res Methodol. 2011;11(1):96–106. doi: 10.1186/1471-2288-11-96
   PubMedGoogle Scholar
• Ouwens MJNM, Mukhopadhyay P, Zhang Y, et al. Estimating lifetime benefits associated with immuno-oncology therapies: challenges and approaches for overall survival extrapolations. Pharmacoeconomics. 2019;37(9):1129–1138. doi: 10.1007/s40273-019-00806-4
   PubMed Web of Science ®Google Scholar
• Royston P, Parmar MK. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med. 2002;21(15):2175–2197. doi: 10.1002/sim.1203
   PubMed Web of Science ®Google Scholar
• Chen J, Hu G, Chen Z, et al. Cost-effectiveness analysis of pembrolizumab plus axitinib versus sunitinib in first-line advanced renal cell carcinoma in China. Clin Drug Investig. 2019;39(10):931–938. doi: 10.1007/s40261-019-00820-6
   PubMed Web of Science ®Google Scholar
• Hoyle M, Green C, Thompson-Coon J, et al. Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma. Value Health. 2010;13(1):61–68. doi: 10.1111/j.1524-4733.2009.00617.x
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wu P, He X, et al. Cost-effectiveness analysis of camrelizumab vs. placebo added to chemotherapy as first-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China. Front Oncol. 2021;11:790373–790381. doi: 10.3389/fonc.2021.790373
   PubMed Web of Science ®Google Scholar
• Zhang PF, Xie D, Li Q. Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma. Future Oncol. 2020;16(17):1189–1198. doi: 10.2217/fon-2019-0821
   PubMed Web of Science ®Google Scholar
• Wu B, Li T, Cai J, et al. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer. 2014;14(1):984–994. doi: 10.1186/1471-2407-14-984
   PubMedGoogle Scholar
• Zhou K, Jiang C, Li Q. Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores. Lung Cancer. 2019;136:98–101. doi: 10.1016/j.lungcan.2019.08.028
   PubMed Web of Science ®Google Scholar
• Shi G, Park SH, Ren H, et al. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China. J Med Econ. 2018;21(12):1150–1158. doi: 10.1080/13696998.2018.1515769
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Cavenagh JD, Belch AR, et al. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma. J Med Econ. 2016;19(3):243–258. doi: 10.3111/13696998.2015.1115407
   PubMed Web of Science ®Google Scholar
• Zhu J, He W, Ye M, et al. Cost-effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung. Future Oncol. 2018;14(27):2833–2840. doi: 10.2217/fon-2018-0321
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Fukuda T, Shimozuma K. Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. Br J Cancer. 2011;105(9):1273–1278. doi: 10.1038/bjc.2011.390
   PubMed Web of Science ®Google Scholar
• Cao X, Cai H, Li N, et al. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis. Ther Adv Med Oncol. 2022;14:17588359221122733–17588359221122735. doi: 10.1177/17588359221122733
   Web of Science ®Google Scholar
• Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008;6(1):84–98. doi: 10.1186/1477-7525-6-84
   PubMed Web of Science ®Google Scholar
• Nafees B, Lloyd AJ, Dewilde S, et al. Health state utilities in non-small cell lung cancer: an international study. Asia Pac J Clin Oncol. 2017;13(5):e195–e203. doi: 10.1111/ajco.12477
   PubMed Web of Science ®Google Scholar
• Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6. Med Decis Making. 2012;32(5):722–732. doi: 10.1177/0272989X12458348
   PubMed Web of Science ®Google Scholar
• Smare C, Lakhdari K, Doan J, et al. Evaluating partitioned survival and Markov decision-analytic modeling approaches for use in cost-effectiveness analysis: estimating and comparing survival outcomes. Pharmacoeconomics. 2020;38(1):97–108. doi: 10.1007/s40273-019-00845-x
   PubMed Web of Science ®Google Scholar
• You M, Huang Y, Cai Z, et al. Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma. Front Oncol. 2022;12:986762–986770. doi: 10.3389/fonc.2022.986762
   PubMed Web of Science ®Google Scholar
• Liu L, Wang L, Chen L, et al. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma. Front Immunol. 2023;14:1092385–1092393. doi: 10.3389/fimmu.2023.1092385
   PubMed Web of Science ®Google Scholar
• Zheng Z, Lin J, Zhu H, et al. Cost-effectiveness analysis of pembrolizumab plus chemotherapy vs. chemotherapy alone as first-line treatment in patients with esophageal squamous cell carcinoma and PD-L1 CPS of 10 or more. Front Public Health. 2022;10:893387–893395. doi: 10.3389/fpubh.2022.893387
   PubMed Web of Science ®Google Scholar
• Liu S, Dou L, Wang K, et al. Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma. Front Oncol. 2022;12:899966–899977. doi: 10.3389/fonc.2022.899966
   PubMed Web of Science ®Google Scholar
• Zheng Z, Fang L, Cai H, et al. Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China. Expert Rev Pharmacoecon Outcomes Res. 2023;23(6):683–690. doi: 10.1080/14737167.2023.2206570
   PubMed Web of Science ®Google Scholar
• Xu K, Wu H, Zhou C, et al. Cost-effectiveness of toripalimab plus chemotherapy for advanced esophageal squamous cell carcinoma. Int J Clin Pharm. 2023;45(3):641–649. doi: 10.1007/s11096-023-01540-w
   PubMed Web of Science ®Google Scholar
• Fang R, Wang S, Liu Y, et al. Cost-effectiveness analysis of toripalimab plus paclitaxel and cisplatin as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma. Adv Ther. 2023;40(3):1019–1030. doi: 10.1007/s12325-022-02402-z
   PubMed Web of Science ®Google Scholar